In a remarkable stride in the fight against cancer, researchers have identified a new inhibitor targeting the Signal Transducer and Activator of Transcription 3 (STAT3), a key protein frequently activated in a number of cancers. The study, recently published in the Biological & Pharmaceutical Bulletin, presents a promising therapeutic avenue for treating tumors characterized by abnormal STAT3 activity.
The Path to Discovery
A team led by Tatsuya Koseki and colleagues at the Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, unveiled 5,5′-(pentane-1,5′-diyl)bis(2-methyl-1,4-benzoquinone) (BPMB) as a novel STAT3 inhibitor. Unlike other compounds, BPMB does not inhibit STAT3 by blocking its phosphorylation or nuclear translocation. Instead, the compound uniquely intervenes by acting on the linker domain of STAT3 proteins.
A Novel Mechanism of Action
STAT3 typically contributes to tumor cell proliferation and survival. Its constant activation is implicated in several cancer types, making it a prime target for anticancer drugs. The researchers found that BPMB selectively hinders the growth of human breast cancer cell lines with constitutively activated STAT3.
Through intricate studies, including gel retardation assays and immunoblotting, the team deduced that BPMB induces the formation of inactive STAT3 complexes by mediating a linkage between two STAT3 proteins. The engagement point identified by the research team is the cysteine residue at position 550 in the STAT3’s linker domain. The inhibitor initiates a Michael addition reaction at this cysteine, leading to the STAT3 dimer formation.
Insights from Gel Retardation and Mass Spectrometry
Immunoblotting results, stable under reducing conditions, indicated that the shifted bands caused by BPMB treatment corresponded to STAT3 but not to related STAT1 or STAT5 proteins. Furthermore, this change was confirmed using purified recombinant STAT3 protein that exhibited similar patterns under the influence of BPMB.
Intriguingly, matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) provided insights into the chemical nature of the modified protein. The mass spectrometry analysis lent credence to the hypothesis that BPMB crosslinks STAT3 through the cysteine residue, providing significant evidence of the inhibitor’s mode of action.
Implications for Cancer Therapy
The implications of this discovery are profound. STAT3 has been a challenging target due to its role in both normal cellular functions and its aberrant activity in cancers. BPMB offers an alternative route to incapacitate STAT3 without interfering with its normal physiological role.
This discovery lays the groundwork for the development of drugs that could effectively treat cancers reliant on STAT3 without affecting healthy cells. The specificity of BPMB could mean fewer side effects for patients and a significant increase in the quality of life during treatment.
The Study’s Significance and Future Research
The meticulous work of Koseki, Suehiro, Masuda, Miyoshi, Muraoka, Ogo, and Asai (2019) embodies a significant step forward in cancer therapeutics. It opens a new pathway for drug development that can lead to more efficient and selective cancer treatments.
Their work underlines the importance of the linker domain in STAT3 as a strategic point of intervention. This domain has been relatively understudied until now, and this discovery underscores its critical role in STAT3 dimerization and function.
Conclusion
The finding of BPMB as a STAT3 inhibitor by Koseki et al. may herald a new era in the treatment of cancers associated with the aberrant activity of STAT3. Further clinical evaluation and drug development are warranted to exploit the full potential of this discovery. But, as of today, hope shines brighter for those seeking novel and effective treatments against the daunting challenge of cancer.
DOI Reference: 10.1248/bpb.b18-00992
References
1. Koseki, T., Suehiro, N., Masuda, Y., Miyoshi, N., Muraoka, D., Ogo, N., & Asai, A. (2019). Discovery of a New STAT3 Inhibitor Acting on the Linker Domain. Biological & Pharmaceutical Bulletin, 42(5), 792-800. doi:10.1248/bpb.b18-00992.
2. Johnston, P. A., & Grandis, J. R. (2011). STAT3 signaling: Anticancer strategies and challenges. Molecular Interventions, 11(1), 18-26.
3. Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews Cancer, 9(11), 798-809.
4. Siddiquee, K. A. Z., & Turkson, J. (2008). STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Research, 18(2), 254-267.
5. O’Shea, J. J., & Plenge, R. (2012). JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity, 36(4), 542-550.
Keywords
1. STAT3 inhibitor
2. Cancer therapy breakthrough
3. BPMB
4. Aberrant STAT3 activity
5. Targeted cancer treatment